Biogen’s Diranersen Shows Promising Tau Reduction in Alzheimer’s Phase 2 Trial — Biogen Inc.

Event summary

Biogen’s diranersen demonstrated meaningful clinical outcomes in the Phase 2 CELIA study, with a 60 mg dose showing a 42% slowing of cognitive decline on ADAS-Cog13 and a 50% slowing on MMSE.
The therapy achieved robust reductions in CSF total tau (50–65%) and brain tau pathology across all studied doses, marking it as the first tau-directed therapy to show such results in a Phase 2 study.
Biogen plans to advance diranersen into confirmatory Phase 3 development based on the consistent body of evidence from Phase 1b and Phase 2 studies.

The big picture

Biogen’s Phase 2 CELIA data for diranersen represent a significant milestone in Alzheimer’s research, as tau reduction has long been a challenging target. The results position Biogen to compete more aggressively in the neurodegenerative disease space, where amyloid-targeting therapies like Aduhelm have faced mixed efficacy and safety outcomes. The shift towards tau-directed mechanisms could redefine treatment paradigms if diranersen’s Phase 3 trials confirm its clinical benefits.

What we're watching

Regulatory Pathway: Whether the FDA’s Fast Track designation will expedite diranersen’s Phase 3 development and potential approval.
Clinical Efficacy: The pace at which diranersen’s clinical benefits are sustained or enhanced in longer-term follow-up studies.
Competitive Landscape: How Biogen positions diranersen against other tau-targeting and amyloid-focused therapies in the Alzheimer’s disease market.